Cibus’ (CBUS) “Buy” Rating Reaffirmed at HC Wainwright

Cibus (NASDAQ:CBUS)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $25.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 373.48% from the company’s previous close.

CBUS has been the topic of a number of other research reports. Canaccord Genuity Group upgraded shares of Cibus to a “strong-buy” rating in a research note on Friday, July 19th. Alliance Global Partners reduced their price objective on shares of Cibus from $25.00 to $23.50 and set a “buy” rating for the company in a research note on Tuesday, September 24th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $20.00 target price on shares of Cibus in a research note on Tuesday, October 22nd.

Cibus Price Performance

NASDAQ:CBUS opened at $5.28 on Monday. Cibus has a one year low of $2.86 and a one year high of $23.18. The business has a fifty day moving average price of $4.08 and a 200-day moving average price of $8.79. The firm has a market capitalization of $121.91 million, a price-to-earnings ratio of -0.23 and a beta of 1.79.

Cibus (NASDAQ:CBUS) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.33). Cibus had a negative return on equity of 29.05% and a negative net margin of 9,856.84%. The company had revenue of $0.84 million during the quarter, compared to analysts’ expectations of $0.44 million. During the same quarter in the previous year, the company earned ($3.05) EPS. On average, equities research analysts expect that Cibus will post -3.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC bought a new stake in shares of Cibus during the second quarter valued at approximately $5,083,000. Bank of New York Mellon Corp bought a new stake in Cibus in the 2nd quarter valued at $529,000. Vanguard Group Inc. increased its holdings in Cibus by 3.7% in the 1st quarter. Vanguard Group Inc. now owns 721,945 shares of the company’s stock valued at $16,215,000 after acquiring an additional 26,017 shares during the last quarter. Rhumbline Advisers purchased a new stake in Cibus in the 2nd quarter worth $221,000. Finally, Squarepoint Ops LLC bought a new position in shares of Cibus during the 2nd quarter valued at about $214,000. 33.81% of the stock is currently owned by institutional investors.

Cibus Company Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.